| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | AL001 Post-Traumatic Stress Disorder (PTSD) | Phase 2 | — | Small Molecules | Nervous System | ||
Phase 2 data readout example | AL001 Post-Traumatic Stress Disorder (PTSD) | Phase 2 | — | Small Molecules | Nervous System | ||
Phase 2 data readout example | AL001 Post-Traumatic Stress Disorder (PTSD) | Phase 2 | — | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Alzamend Neuro, Inc.$1.2
-0.09 (-6.98%)
D 22Pipeline Score Richly Valued Pharma · Clinical
Market Cap
4.34 M
EPS
-4.38
P/E Ratio
-0.26 $
Value Trade
38.93 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.28 M
Total Assets
4.04 M
Total Liabilities
1.86 M
Equity
2.18 M
D/E Ratio
12,345
11.88 %
Week
2.73 %
1 Month
-43.5 %
3 Month
-43.5 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
2.71 M
Monthly Burn
733.00 K
Runway
0.2 mo
Burn Trend
SEC Filing
Mar 11, 2026
Overview
Volume
68.92 K
52 Week Range
0.84 - 4.03
% held by Insiders
16.05 %
% held by Institutions
3.04 %
Enterprise Value
1.62 M
Total Shares
3.81 M
Short %
3.34 %
Float Shares
3.75 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D22
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 21%
Micro Cap (rank 716 of 905)
Percentile RankAlzamend Neuro, Inc. faces pipeline headwinds (22/100), with $51M risk-adjusted pipeline value, led by AL001 in Bipolar I Disorder (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AL001 Small molecule | Pharmacokinetics | Phase 1 | NCT06921590 | 7% | $51M | ACTIVE NOT_RECRUITING | 6 | STALLED | D (38) | Dec 1, 2025 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AL001 | Alzheimer's,bipolar disorder,major depressive disorder,post-traumatic stress disorder | Phase 2 | 2025-07-29 | |||
AL001 | Alzheimer's,bipolar disorder,major depressive disorder,post-traumatic stress disorder | Phase 2 | 2025-07-29 | |||
AL001 | Alzheimer's,bipolar disorder,major depressive disorder,post-traumatic stress disorder | Phase 2 | 2025-07-29 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALZN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Alzamend Neuro, Inc. (ALZN) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ALZN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALZN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALZN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALZN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ALZN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALZNAlzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro, a clinical-stage biopharmaceutical company, will present a poster at the Military Health System Research Symposium from August 4-7, 2025. The presentation will focus on the differences in lithium exposure in PTSD subjects between AL001 and lithium carbonate. This research aims to improve treatment strategies for various mental health disorders, including Alzheimer's and PTSD.
Read more →ALZNAlzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro reported its annual financial results and provided updates on its clinical programs, highlighting a successful $5 million financing deal completed ahead of schedule. The company is advancing its lead drug candidate, AL001, through five Phase II clinical trials in collaboration with prestigious institutions. However, it faces challenges in securing a new contract research organization for its secondary candidate, ALZN002.
Read more →ALZNAlzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Alzamend Neuro has successfully completed a $5 million private placement, finalizing the deal months ahead of schedule. The funds will support five Phase II clinical trials for its lead candidate, AL001, targeting Alzheimer's disease and other mental health disorders. The first trial has already commenced, with topline data expected by the end of 2025.
Read more →ALZNAlzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro has announced the dosing of the first patient in its Phase II clinical trial for AL001, a novel lithium delivery system. Conducted at Massachusetts General Hospital, this trial aims to evaluate AL001's effectiveness in delivering lithium more effectively to the brain while minimizing systemic side effects. The study could lead to improved treatment options for patients with Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.
Read more →ALZNAlzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro has enrolled its first patient in a Phase II clinical trial for AL001, a novel lithium delivery system aimed at improving treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. The trial, conducted in collaboration with Massachusetts General Hospital, will compare AL001's pharmacokinetics in healthy subjects against existing lithium carbonate products. With topline data expected by year-end, the study seeks to demonstrate AL001's targeted effectiveness and reduced side effects, potentially transforming care for over 43 million affected Americans. This development follows promising preclinical results indicating better brain absorption of lithium and lower blood levels in mice.
Read more →ALZNAlzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro has launched its first Phase II clinical trial for AL001, targeting Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. This trial, conducted at Massachusetts General Hospital, aims to assess AL001's effectiveness in delivering lithium more effectively in the brain compared to traditional lithium products. Previous studies indicated that AL001 provides better brain absorption while minimizing systemic side effects. The results are expected by the end of the year, potentially offering a safer and more efficient treatment option for patients.
Read more →ALZNAlzamend Neuro Announces Reverse Stock Split
Alzamend Neuro, Inc. announced a one-for-nine reverse stock split effective May 12, 2025, to comply with Nasdaq's minimum bid price requirement. This action will reduce the number of outstanding shares while maintaining the par value. The company aims to enhance its market position and investor confidence amidst ongoing development of treatments for Alzheimer's and other disorders.
Read more →ALZNAlzamend Neuro Announces Reverse Stock Split ATLANTA, GA
Alzamend Neuro has announced a one-for-nine reverse stock split of its common stock, effective May 12, 2025, to comply with Nasdaq's minimum bid price requirement. This move is part of the company's broader strategy to maintain its listing on the exchange while developing innovative treatments for conditions such as Alzheimer's disease, bipolar disorder, and PTSD. The split will affect all shares uniformly, but those entitled to fractional shares will receive cash payments instead. The change comes amidst the backdrop of Alzamend's continued efforts to advance its drug candidates.
Read more →ALZNAlzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
Alzamend Neuro has partnered with QMENTA to utilize AI-powered imaging in its Phase II clinical trials of AL001 at Massachusetts General Hospital. This collaboration aims to optimize the imaging workflow and enhance data management for the trials. AL001 is designed to improve lithium delivery in the brain, potentially offering safer treatment options for Alzheimer's and other psychiatric disorders.
Read more →ALZNAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Alzamend Neuro has announced the initiation of a Phase II clinical trial for AL001, aimed at treating Alzheimer's disease. The trial, set to begin in Q4 2025 at Massachusetts General Hospital, follows promising results from earlier studies. AL001 is designed to improve lithium delivery in the brain while minimizing side effects, potentially transforming treatment for Alzheimer's patients.
Read more →ALZNAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro has announced the initiation of a Phase II clinical trial for AL001, aimed at treating major depressive disorder (MDD). The trial, set to begin in Q4 2025 at Massachusetts General Hospital, follows successful preliminary studies. AL001 is designed to improve lithium delivery in the brain while reducing systemic side effects, potentially transforming MDD treatment.
Read more →ALZNAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro, Inc. has announced the initiation date of a Phase II clinical trial for AL001, aimed at treating post-traumatic stress disorder (PTSD) at Massachusetts General Hospital. This trial follows successful preclinical work indicating that AL001 may allow for enhanced lithium delivery with reduced systemic side effects. The company aims to demonstrate AL001's effectiveness as a next-generation therapy, potentially easing treatment for over 9 million Americans suffering from PTSD. This initiative may also alleviate the complexities associated with traditional lithium monitoring, which could reshape treatment paradigms in the field.
Read more →ALZNAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro has announced the initiation date for its Phase II clinical trial of AL001, aimed at treating bipolar disorder. Set to commence in Q3 2025, the study will be conducted in collaboration with Massachusetts General Hospital, focusing on AL001's unique lithium delivery system. The new formulation promises enhanced safety and effectiveness compared to traditional lithium treatments, which often require complex monitoring. Early research indicates that AL001 may improve brain absorption while minimizing systemic side effects, offering a potentially groundbreaking alternative for over 7 million Americans suffering from bipolar disorder.
Read more →ALZNAlzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Alzamend Neuro has announced the initiation of its first Phase II clinical trial for AL001, which is set to commence in the second quarter of 2025. This study, conducted in collaboration with Massachusetts General Hospital, aims to evaluate the unique properties of AL001 regarding lithium delivery in the brain. The novel formulation potentially offers improved safety and effectiveness by reducing systemic side effects associated with traditional lithium treatments. AL001 represents a significant step forward in the management of Alzheimer's disease and related disorders.
Read more →ALZNAlzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs During the six months ended
Alzamend Neuro has reported its financial results for the second quarter of 2025, showcasing improved financial health due to strategic partnerships and capital management. The company has secured agreements to sell preferred stock and warrants, which has strengthened its stockholder equity and reduced liabilities. Alzamend is advancing its lead candidate, AL001, through multiple upcoming Phase II trials starting in 2025, aiming to improve lithium therapies for neurodegenerative conditions. Additionally, their alternate candidate, ALZN002, aims to enhance immunotherapy for Alzheimer's, with trial resumptions planned for next year.
Read more →ALZNAlzamend Neuro Regains Compliance with Nasdaq Listing Standards ATLANTA, GA
Alzamend Neuro has announced that it has regained compliance with Nasdaq's listing standards after meeting the minimum stockholders' equity requirement. The company received a written notice from Nasdaq confirming its compliance after an appeal process that began when it failed to meet the requirements in 2023. This development allows Alzamend to continue its listing on the Nasdaq Capital Market and supports its ongoing clinical trials aimed at treating Alzheimer's disease and other conditions. Alzamend is now focused on advancing its product candidates with plans to initiate phase II clinical trials in 2025.
Read more →ALZNAlzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement ATLANTA, GA
Alzamend Neuro has announced that it has regained compliance with the Nasdaq's Minimum Bid Price Requirement after maintaining a bid price above $1.00 for ten consecutive trading days. This compliance was confirmed in a notification letter from Nasdaq dated July 30, 2024. Previously, Alzamend faced challenges regarding its Market Value of Listed Securities and was notified of potential delisting. The company must still demonstrate compliance with other Nasdaq requirements by September 2024 to maintain its listing.
Read more →ALZNAlzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel ATLANTA, GA
Alzamend Neuro, a clinical-stage biopharmaceutical company, announced that it has been granted a favorable decision from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market. The company must demonstrate compliance with the Stockholder Equity Rule by September 23, 2024. CEO Stephan Jackman expressed appreciation for the Panel's consideration and stated that they are implementing their compliance plan. Alzamend focuses on developing innovative treatments for Alzheimer's and other mental health disorders.
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation May 2024 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or "Al
Alzamend Neuro, Inc. provided a corporate presentation highlighting developments in their clinical pipeline, particularly regarding their lead drug candidate, AL001, an ionic cocrystal of lithium. This candidate is positioned as a potential replacement for marketed lithium therapies, with a target patient population spanning multiple indications including Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company anticipates initiating Phase II clinical studies in these areas, bolstered by recent positive feedback from the FDA. However, they acknowledge inherent risks and uncertainties affecting their forecasts and projections.
Read more →ALZNAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million ATLANTA, GA
Alzamend Neuro has entered into a Securities Purchase Agreement for a registered direct offering and concurrent private placement, potentially raising up to $25 million. The funds are intended to initiate clinical trials for two of its product candidates targeting Alzheimer's and other disorders. The issuance includes senior Preferred Shares and warrants for common stock, with specific conversion options. The offering is expected to close on or about May 10, 2024, subject to regulatory conditions.
Read more →ALZNAlzamend Neuro Announces Termination of At-the-Market Equity Offering Program ATLANTA, GA
Alzamend Neuro, a clinical-stage biopharmaceutical company, has announced the termination of its at-the-market equity offering program with Ascendiant Capital Markets. The decision to terminate the program is aimed at reducing uncertainty and potential unfavorable dilution for stockholders. The termination process commenced today, with the official termination scheduled for May 16, 2024. Prior to this decision, Alzamend had sold over a million shares, raising about $1.3 million in gross proceeds.
Read more →ALZNAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement ATLANTA, GA
Alzamend Neuro received an extension from the Nasdaq Hearings Panel to comply with the minimum bid price requirement, allowing the company additional time until November 15, 2023. To regain compliance, Alzamend plans to conduct a reverse stock split pending stockholder approval at a meeting scheduled for September 29, 2023. Despite the granted extension, Alzamend must still overcome financial challenges, including requirements related to stockholder equity and meeting the bidding price over ten consecutive business days. Their ability to successfully comply remains uncertain.
Read more →ALZNAlzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 Topline data identifies maximum tolerated dose from Phase IIA multiple ascending dose study as assessed by an independent safety review committ
Alzamend Neuro has announced positive results from a Phase IIA clinical trial for AL001, a novel lithium-delivery system. The study successfully identified a maximum tolerated dose, assessed as safe by an independent review committee. This development brings potential benefits for treating conditions like Alzheimer's, bipolar disorder, and PTSD without the need for therapeutic drug monitoring. Alzamend plans to initiate additional clinical trials to further evaluate AL001's safety and efficacy by early 2024.
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation April 2023 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or "
Alzamend Neuro, Inc. presented a corporate update highlighting its lead drug candidate, AL001, an ionic cocrystal of lithium, which has completed Phase I clinical studies. The company is preparing to submit Investigational New Drug applications in Q4 2023 for conditions including Bipolar Disorder and Major Depressive Disorder. Alzamend emphasized the significant market potential for its therapies targeting Alzheimer's disease, among other indications. However, they also noted the importance of caution regarding forward-looking statements due to inherent risks and uncertainties in clinical and market environments.
Read more →ALZNAlzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type ATLANTA, GA
Alzamend Neuro has announced the start of a Phase I/IIA clinical trial for its immunotherapy vaccine, ALZN002, aimed at treating mild to moderate dementia of the Alzheimer's type. This trial will evaluate the safety, tolerability, and efficacy of the vaccine using multiple ascending doses in a cohort of 20-30 subjects. ALZN002 utilizes the patient's own dendritic cells to target amyloid-beta proteins, aiming to offer a robust and long-lasting effect compared to traditional treatments. Encouraging pre-clinical results support its potential as a new therapeutic option for Alzheimer's disease.
Read more →ALZNAlzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's Topline data expected in June 2023 ATLANTA, GA
Alzamend Neuro has completed the clinical portion of its Phase IIA multiple ascending dose trial for AL001, a treatment for dementia related to Alzheimer's. The trial aimed to evaluate the safety and tolerability of AL001, which utilizes a novel lithium-delivery system aimed at addressing cognitive impairment. Topline data from the trial is expected to be reported in June 2023, as the company seeks to further develop this promising therapeutic. This treatment could potentially benefit a significant number of individuals suffering from Alzheimer's and other related conditions.
Read more →ALZNAlzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update Company had $7.4 Million Cash at
Alzamend Neuro, an early clinical-stage biopharmaceutical company, reported its third fiscal quarter financial results and provided updates on its clinical trials for AL001 and ALZN002, both targeting Alzheimer's and related conditions. The company anticipates topline data from the Phase IIA trial of AL001 by June 2023 and plans to commence a Phase I/IIA trial for ALZN002 aimed at treating mild to moderate Alzheimer's dementia. Alzamend currently holds $7.4 million in cash and expects $14.8 million from a note receivable in 2023. The updates highlight the company's focus on developing innovative therapies while maintaining a low operational burn rate.
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation January 2023 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or
Alzamend Neuro, Inc. has provided an update on its corporate presentation that highlights its lead drug candidate, AL001, which is undergoing a Phase IIA clinical study for Alzheimer's Disease. The company received positive feedback from the FDA regarding its Pre-IND application for multiple psychiatric indications. However, the presentation outlines inherent risks and uncertainties that could impact the future success of the candidate, including challenges in clinical trial completion and market competition.
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation November 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" o
Alzamend Neuro, Inc. Corporate Presentation November 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or "Alzamend") contain "forward looking statements" within t
Read more →ALZNAlzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Typ
Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type ATLANTA, GA, October 31, 2022 -- Alzamend Neuro, Inc.
Read more →ALZNAlzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's Subjects Alzamend pursuing additional indications of bipolar disorder, major depressive disorder and post
Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's Subjects Alzamend pursuing additional indications of bipolar disorder, major depressive disorder and post-traumatic stress disorder for AL001 ATLANTA, GA, October 5, 2022 -- Alz
Read more →ALZNAlzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type ATLANTA, GA
Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's ATLANTA, GA, September 29, 2022 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on d
Read more →ALZNAlzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement ATLANTA, GA
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement ATLANTA, GA, September 22, 2022 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation August 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or
Alzamend Neuro, Inc. Corporate Presentation August 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or " Alzamend ") contain "forward looking statements" within t
Read more →ALZNAlzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder Topline data expected in December 2022 from Phase IIA Multi
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder ATLANTA, GA, July 18, 2022 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage biopharmaceu
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation June 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or "
Alzamend Neuro, Inc. Corporate Presentation June 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or " Alzamend ") contain "forward looking statements" within the
Read more →ALZNAlzamend Neuro, Inc. Corporate Presentation April 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or "
Alzamend Neuro, Inc. Corporate Presentation April 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or " Alzamend ") contain "forward looking statements" within
Read more →ALZNAlzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's Data show that AL001 is bioequivalent to the marketed lithium carbonate pro
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's Data show that AL001 is bioequivalent to the marketed lithium carbonate product and the shapes of the lithium plasma concentration v
Read more →ALZNAlzamend Neuro Receives Positive Pre-IND Response From FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease FDA Agrees to Alzam
Alzamend Neuro Receives Positive Pre-IND Response From FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat FDA Agrees to Alzamend's Plan to Conduct a Combined Phase 1 and 2 Clinical Trial for AL002 TAMP
Read more →ALZNAlzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer's Disease in September 2021 TAMPA, FL.
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer's Disease in September TAMPA, FL., August 17, 2021-Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-s
Read more →ALZNAlzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending Tampa,
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending Tampa, FL, August 4, 2021 - Alzamend Neuro, Inc. (Nasdaq: ALZN)
Read more →ALZNAlzamend Neuro Receives FDA "Study May Proceed" Letter for Phase 1 Clinical Study Under its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease TAMPA, FL.
Receives FDA "Study May Proceed" Letter for Phase 1 Clinical Study Under its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease TAMPA, FL., July 28, 2021--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage stage bi
Read more →ALZNAlzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease AL002 is a Patented Method Using a Mutant-Peptide Sensitized Cell as a Cell-Based Therape
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease AL002 is a Patented Method Using a Mutant-Peptide Sensitized Cell as a Cell-Based Therapeutic Vaccine TAMPA, FL, July 23, 2021 -- Alzamend Neuro,
Read more →ALZNAlzamend Neuro™ Completes New Management Team for 2019
Tampa, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its new Chief Financial Officer (CFO) and Treasurer. Mr. Cragun will report directly to
Read more →ALZNAlzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman
Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a full-time pr
Read more →ALZNAlzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in t
Read more →ALZNAlzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory application and oversight efforts including the successful filing of a FDA IND application
Read more →ALZNAlzamend Neuro™ Announces TV Icon Willie Aames as International Spokesperson
SALT LAKE CITY, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today Willie Aames will serve as its International Spokesperson while joining the team as Creative Advisor. The Company stated that with its recent launch of its Regulat
Read more →ALZNAlzamend Neuro Launches Regulation A+ Tier II SEC Qualified Offering
SALT LAKE CITY, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Alzamend) announced today it has launched its Regulation A+ Tier II Offering online at www.AlzamendRegA.com. The Company’s campaign targeted to raise $50M in equity capital to take investment immediately. On
Read more →Competitive Position
How ALZN ranks across every disease it competes inCompetitive Position is a premium feature
See how ALZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial